NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration
Date of first enrollment	07/06/2013
Target sample size	20
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : OPC-41061 INN of investigational material : Tolvaptan Therapeutic category code : 213 Diuretics Dosage and Administration for Investigational material : The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast

Outcome(s)

Primary Outcome	daily urine volume Change and percent change from baseline
Secondary Outcome	Total fluid removal per week by dialyses Change and percent change from baseline

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	<= 80age old
Gender	Both
Include criteria	1)Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration three times a week 2)Subjects between the ages of 20 and 80, inclusive (at time of informed consent) 3)Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period 4)Subjects who, together with their partner, are able to practice one of the specified contraceptive methods until 4 weeks after the final trial drug administration 5)Patients who are capable of providing written informed consent themselves before any trial-related procedures are performed
Exclude criteria	1)Subjects with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause 2)Subject with daily urine volume less than 500 mL 3)Subject with Cardiac function of NYHA class 4 4)Subjects with serious ischemic heart disease, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial 5)Subjects with serious arrhythmia, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial 6)Subjects who are concomitantly undergoing peritoneal dialysis 7)Subjects with ascites due to cirrhosis or cancer, requring medical treatments 8)Subjects with any of the following medical histories: - History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to informed consent - History of hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride 9)Subjects with any of the following abnormal laboratory values: - Hemoglobin lower than 8.0 g/dL, total bilirubin higher than 3.0 mg/dL, ALT (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125mEq/L 10)Subjects with serum potassium higher than 6.0mEq/L and abnormal findings inappropriate for inclusion in the trial are observed by 12-lead ECG 11)Subjects who are unable to sense thirst or who have difficulty with fluid or food intake 12)Subjects who have participated in any other clinical trial or post-marketing clinical studies within 4 weeks prior to informed consent 13)Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period 14)Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial